Accolade Inc., a personalized healthcare company, exceeded expectations for its second quarter of fiscal year 2025, reporting a revenue increase of 10% and a narrower adjusted EBITDA loss. The company also provided guidance for the third quarter and full fiscal year, indicating a path toward profitability. Despite the positive earnings, Accolade’s stock has significantly declined this year, with analysts lowering their price targets.